- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| APREA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| Mi | Aprea Therapeutics: Aprea Reports Anti-Proliferative Results and Promising Early-Stage Clinical Data for Next-Generation WEE1 Inhibitor, APR-1051, in HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Collaboration with ... | 40 | GlobeNewswire (Europe) | Preclinical data demonstrate potent single-agent and combination effects in head and neck squamous cell carcinoma (HNSCC) models, including synergy with anti-PD-1 therapy Initial Phase 1 clinical... ► Artikel lesen | |
| 09.06. | Aprea Therapeutics, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 14.05. | Aprea Therapeutics GAAP EPS of -$0.66 | 1 | Seeking Alpha | ||
| 14.05. | Aprea Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 14.05. | Aprea Therapeutics Reports First Quarter 2025 Financial Results and Provides a Clinical Update | 89 | GlobeNewswire (Europe) | ATRN-119, our ATR inhibitor, exhibits early evidence of single agent, anti-tumor activity and is progressing toward the recommended Phase 2 dose (RP2D) in the ongoing ABOYA-119 clinical trial ... ► Artikel lesen | |
| 14.05. | Aprea Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 25.03. | Aprea Therapeutics GAAP EPS of -$0.49 beats by $0.20, revenue of $0.21M beats by $0.06M | 1 | Seeking Alpha | ||
| 25.03. | Aprea Therapeutics, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 25.03. | Aprea Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 25.03. | Aprea Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update | 166 | GlobeNewswire (Europe) | ACESOT-1051 trial evaluating WEE1 kinase inhibitor APR-1051 now enrolling patients in Cohort 5; open label safety and efficacy data expected H2 2025 Twice daily (BID) dosing regimen in ongoing ABOYA-119... ► Artikel lesen | |
| 12.03. | Aprea and MD Anderson sign agreement for APR-1051 | 1 | Pharmaceutical Business Review | ||
| 11.03. | Aprea Therapeutics Announces Agreement with MD Anderson Cancer Center to Explore APR-1051 as a Potential Treatment for Head and Neck Squamous Cell Carcinoma (HNSCC) | 162 | GlobeNewswire (Europe) | DOYLESTOWN, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) ("Aprea", or the "Company"), a clinical-stage biopharmaceutical company developing innovative treatments... ► Artikel lesen | |
| 05.02. | Aprea Therapeutics erweitert Patent-Portfolio für Krebsmedikamente | 4 | Investing.com Deutsch | ||
| 05.02. | Aprea Therapeutics expands cancer drug patent portfolio | 3 | Investing.com | ||
| 05.02. | Aprea Therapeutics Announces Strategic IP Portfolio Evolution in DNA Damage Response (DDR) Cancer Therapeutics | 1 | GlobeNewswire (USA) | ||
| 05.02. | Aprea Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 13.01. | Aprea Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 11.12.24 | Aprea Therapeutics Announces Twice Daily (BID) Dosing of Patients in ABOYA-119 Clinical Trial of ATRN-119 to Potentially Optimize Clinical Outcomes and Strengthen Clinical Path Forward | 237 | GlobeNewswire (Europe) | Twice daily (BID) dosing regimen expected to maximize clinical benefit for patients by optimizing the activity of Aprea's experimental drug, ATRN-119, over a 24-hour daily cycle New regimen potentially... ► Artikel lesen | |
| 12.08.24 | Aprea Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update | 182 | GlobeNewswire (Europe) | Enrollment commenced in the ACESOT-1051 Phase 1 trial evaluating APR-1051 - no myelosuppression observed in the first of eight planned cohorts at sub-therapeutic dose $28.7 million in cash and cash... ► Artikel lesen |
19 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 7,160 | +4,04 % | BioNTech schluckt CureVac! Evotec und Vidac als nächstes? Kurstreiber Übernahme und Kaufempfehlung | Steht bei Vidac Pharma eine neue Kursexplosion bevor? Im vergangenen Herbst ging es um rund 200 % nach oben. Gestern gab es eine Kaufempfehlung. Die Analysten sehen bei der Biotech-Perle Vervielfachungspotenzial.... ► Artikel lesen | |
| BB BIOTECH | 32,100 | -0,62 % | EQS-PVR: BB BIOTECH AG: Disclosure of Shareholdings | EQS Voting Rights Announcement: BB BIOTECH AG
Disclosure of Shareholdings
23.06.2025 / 07:00 CET/CEST
Dissemination of a Voting Rights Announcement... ► Artikel lesen | |
| CUREVAC | 4,650 | +0,09 % | EQS-News: CureVac Announces Voting Results of General Meeting | Emittent / Herausgeber: CureVac
/ Schlagwort(e): Hauptversammlung
CureVac Announces Voting Results of General Meeting
24.06.2025 / 22:09 CET/CEST
Für den Inhalt der... ► Artikel lesen | |
| VALNEVA | 2,500 | -1,03 % | Valneva Announces Successful Outcome of its Annual General Meeting, Confirms FY 2025 guidance | Saint-Herblain (France), June 25, 2025 - Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that all the resolutions recommended by the Board of Directors... ► Artikel lesen | |
| BIOGEN | 109,10 | -0,14 % | Biogen Inc.: Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results | Salanersen (BIIB115/ION306) is a novel antisense oligonucleotide (ASO) with the potential to achieve high efficacy and once yearly dosing in spinal muscular atrophy (SMA)Interim Phase 1 data show children... ► Artikel lesen | |
| ILLUMINA | 80,82 | +1,02 % | Standard BioTools Inc.: Standard BioTools Enters Next Phase of Transformation with Strategic Sale of SomaLogic to Illumina | Up To $425 Million In Total Proceeds Inclusive of Near-term Milestone Payments; $350 Million In Upfront Cash Retains Strategic Upside with Illumina Protein Prep Royalty Stream and Rights to Single... ► Artikel lesen | |
| GINKGO BIOWORKS | 8,100 | +1,25 % | Ginkgo Bioworks stock rises on Hugging Face collaboration for AI drug development | ||
| ONCO-INNOVATIONS | 1,210 | +0,83 % | CEO von Onco-Innovations hält am Mittwoch, den 2. Juli 2025 eine Sondertelefonkonferenz für Investoren ab | Vancouver, Kanada - 25. Juni 2025 / IRW-Press / Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) ("Onco" oder das "Unternehmen") freut sich bekannt zu geben... ► Artikel lesen | |
| QIAGEN | 40,130 | -0,59 % | Minimale Kursveränderung bei Qiagen NV-Aktie (40,55 €) | Am Aktienmarkt ist der Anteilsschein von Qiagen NV gegenwärtig unauffällig. Das Wertpapier kostete zuletzt 40,55 Euro. Der heutige Börsentag brachte bislang wenig Kursbewegung bei der Aktie von Qiagen... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 46,470 | -1,42 % | Gilead Sciences Partners Kymera Therapeutics To Develop Novel Oral Molecular Glue CDK2 Degraders | FOSTER CITY (dpa-AFX) - Gilead Sciences, Inc. (GILD) and Kymera Therapeutics, Inc. (KYMR) announced Wednesday that they have entered into an exclusive option and license agreement to accelerate... ► Artikel lesen | |
| COGENT BIOSCIENCES | 7,070 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Secures up to $400 Million in Non-Dilutive Financing | ||
| SPRINGWORKS THERAPEUTICS | 46,970 | +0,02 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Receives Positive CHMP Opinion for Nirogacestat for the Treatment of Adults with Desmoid Tumors | - If approved, nirogacestat will be the first and only therapy with marketing authorization in the EU for the treatment of desmoid tumors -
- Decision from European Commission expected in the third... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 28,380 | -2,34 % | Kiniksa Pharmaceuticals, Ltd.: Kiniksa Pharmaceuticals Announces Trial Design of Planned Phase 2/3 Clinical Trial of KPL-387 in Recurrent Pericarditis | - KPL-387 Phase 2/3 trial on track to initiate in mid-2025; Phase 2 data expected in 2H 2026 -- KPL-387 Phase 1 single ascending dose data support profile for monthly dosing -- Presentation and webcast... ► Artikel lesen | |
| BIONTECH | 89,70 | -0,11 % | Biotech Report: Biontech rutschen ab; Sektor an der Wall Street leichter | (shareribs.com) Frankfurt / New York 23.06.2025 - Biotech-Aktien zeigen sich im deutschen Handel überwiegend leichter. Unter anderem sacken Biontech kräftig ab. Auch an der Wall Street bewegt sich der... ► Artikel lesen | |
| REGENCELL BIOSCIENCE | 21,760 | 0,00 % | Tesla, Regencell lead market cap stock movers this Monday |
Das Unternehmen APREA THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 1,740 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu APREA THERAPEUTICS INC finden Sie auf Wallstreet Online.